dydrogesterone / Generic mfg. - LARVOL DELTA

Comparison of the effect of combination of alprosterone and dydrogesterone on luteal support after fresh cycle transplantation (ChiCTR) - P=N/A | N=216 | Not yet recruiting | Sponsor: The Second Affiliated Hospital Of Zhengzhou University; The Second Affiliated Hospital Of Zhengzhou University

New trial • Infertility • Sexual Disorders • Transplantation

RETRACTION: Comparison of the Effect of Dydrogesterone and Natural Micronized Progesterone for Luteal-Phase Support in Assisted Reproductive Technology Cycles: A Single-Blind Randomized Clinical Trial Study. (PubMed, Health Sci Rep) - "[This retracts the article DOI: 10.1002/hsr2.2296.]."

Clinical • Journal

Reproductive outcome after frozen embryo transfer with hormone replacement therapy according to luteal-phase support protocol: systematic review and network meta-analysis of randomized controlled trials. (PubMed, Ultrasound Obstet Gynecol) - "There is very-low-to-low-certainty evidence that oral DYD + GnRHa and vaginal suppository progesterone alone could be the most promising LPS approaches to increase the rates of live birth and ongoing pregnancy in women undergoing HRT-FET. However, the low certainty of evidence and the lack of a clear first-ranked treatment, due to inconsistencies in the analysis for some outcomes, stress the need for further RCTs on this subject."

Journal • Retrospective data • Review • Gynecology • Infertility • Obstetrics • Sexual Disorders

Spontaneous ovulation, hormonal profiles, and the impact of progesterone timing variation on outcomes in natural proliferative phase frozen embryo transfer cycles with single euploid blastocyst transfer. (PubMed, J Ovarian Res) - "Flexible dydrogesterone initiation at follicular diameters ≥ 14 mm, based on predefined criteria, preserves spontaneous ovulation and natural hormonal dynamics. Pregnancy outcomes were consistent across P4 initiation timings, supporting NPP-FET as a clinically viable, physiologically grounded, and scheduling-friendly protocol."

Journal • Retrospective data • Obstetrics

A novel fertility-sparing nanocomposite for endometriosis treatment via oxidative stress and inflammation alleviation. (PubMed, Mater Today Bio) - "Herein, we engineered a nanocomposite with polydopamine and dydrogesterone for precise and gentle endometriosis treatment while protecting ovarian function and fertility...Importantly, this therapeutic approach preserves ovarian reserve function and fertility, showing no significant adverse effects on ovarian health. In summary, we present an innovation non-surgical therapeutic strategy for endometriosis that demonstrates both safety and efficacy while preserving ovarian reserve function and fertility potential."

Journal • Endometriosis • Gynecology • Infertility • Inflammation • Pain • Sexual Disorders • Women's Health

Intensive luteal phase support in hormone replacement and modified natural cycle frozen embryo transfers in ovulatory patients: A propensity score-matched study. (PubMed, PLoS One) - "In ovulatory women undergoing FET with intensive luteal phase support, the use of HRT or mNC for endometrial preparation yields comparable pregnancy and live birth rates."

Journal • Retrospective data

Efficacy and safety of recombinant human granulocyte colony-stimulating factor in patients with unexplained recurrent pregnancy loss: a protocol for a multicenter, randomized, double-blind, controlled trial. (PubMed, Trials) - P=N/A | "This trial aims to provide high-quality evidence on the efficacy and safety of G-CSF in the treatment of uRPL, particularly in the Chinese population where existing data are limited. The findings may support evidence-based recommendations and inform treatment decisions in a population where therapeutic options remain limited and controversial."

Clinical • Journal • Diabetes • Gestational Diabetes • Gynecology • Metabolic Disorders

Pharmacological Treatments for Menopausal Vasomotor Symptoms: A Systematic Review and Bayesian Network Meta-Analysis of Efficacy and Safety. (PubMed, Eur J Obstet Gynecol Reprod Biol) - "Conjugated estrogens and drospirenone with estradiol are the most effective options for reducing VMS frequency and severity, and Fezolinetant and Elinzanetant showed moderate efficacy, with overall similar safety across treatments."

Journal • Retrospective data • Review

Three different protocols for pituitary suppression: progestins (dydrogesterone or medroxyprogesterone acetate) versus GnRH antagonist-balancing efficacy and cost in ovarian stimulation. (PubMed, J Assist Reprod Genet) - "PPOS protocols (DYD or MPA) offer clinical outcomes comparable to the GnRH antagonist protocol. While PPOS regimens may provide cost advantages in freeze-all settings due to lower LH suppression, the overall economic benefit hinges on the embryo transfer strategy. Therefore, optimal protocol selection should be individualized, considering both clinical characteristics and cost."

Journal • Gynecology

Comment on: Fewer good-quality cleavage embryos in dydrogesterone-primed ovarian stimulation compared to GnRH antagonist protocol in POSEIDON group 4 patients. (PubMed, J Formos Med Assoc) - No abstract available

Journal

Cumulative Live Birth Rates in Women Undergoing Progestin-Primed Ovarian Stimulation Using Medroxyprogesterone Acetate, Dydrogesterone, and Progesterone: A Retrospective Analysis. (PubMed, Drug Des Devel Ther) - "Patients received oral progestins once daily as per their assigned protocol with human menopausal gonadotropin initiated on menstrual cycle day 3. Our findings establish clinical equivalence in cumulative live birth outcomes among MPA, DYG, and Progesterone when implemented within the PPOS framework. This evidence supports protocol flexibility in progestin selection, enabling personalized decisions based on pharmacological characteristics, cost considerations, and patient tolerance."

Journal • Retrospective data

Comparing Dydrogesterone Versus Medroxyprogesterone in Progestin-Primed Ovarian Stimulation (PPOS) for Patients Undergoing In Vitro Fertilization/Intracytoplasmic Sperm Injection: A Systematic Review. (PubMed, Cureus) - "These findings indicate that both DYG and MPA are effective and safe for LH surge suppression in PPOS protocols, with DYG potentially offering a more physiologic hormonal profile and reduced gonadotropin use. Further randomized controlled trials are recommended to validate these results."

Journal • Preclinical • Review • Gynecology

Comment on: Fewer good-quality cleavage embryos in dydrogesterone-primed ovarian stimulation compared to GnRH antagonist protocol in POSEIDON group 4 patients. (PubMed, J Formos Med Assoc) - No abstract available

Journal

Oral Dydrogesterone as Luteal Phase Support in Natural Cycle FET (clinicaltrials.gov) - P3 | N=716 | Recruiting | Sponsor: The University of Hong Kong | Trial completion date: Nov 2025 ➔ Nov 2026 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date • Infertility

Reply: Fetal safety of dydrogesterone: clarifying the role of pharmacovigilance. (PubMed, Hum Reprod Open) - No abstract available

Adverse events • Journal

Why does the latest pharmacovigilance data not reflect clinical experience with dydrogesterone? (PubMed, Hum Reprod Open) - No abstract available

Adverse events • Journal

Long-Term Outcomes of Dydrogesterone in Postoperative Endometriosis：A Real-World Study (ChiCTR) - P=N/A | N=332 | Not yet recruiting | Sponsor: Women’s Hospital, Zhejiang University School of Medicine; Women’s Hospital, Zhejiang University School of Medicine

New trial • Real-world evidence • Endometriosis • Gynecology • Women's Health

To explore the mechanism of acupuncture intervention on insulin resistance of phlegm-dampness polycystic ovary syndrome based on oxidative homeostasis (ChiCTR) - P=N/A | N=66 | Recruiting | Sponsor: Fujian Maternal and Child Health Care Hospital; Fujian Maternal and Child Health Care Hospital

New trial • Polycystic Ovary Syndrome

Ovarian Responses and Outcomes of In Vitro Fertilization Following Progesterone-Primed Ovarian Stimulation and Gonadotropin-Releasing Hormone (GnRH) Antagonist Protocols Using Follitropin Delta. (PubMed, Cureus) - "Both the GnRH antagonist and PPOS protocols demonstrated trends toward higher numbers of retrieved oocytes and blastocysts, with comparable pregnancy rates across all age groups, suggesting similar clinical outcomes. A key limitation of this study is its retrospective design at a single institution; therefore, future prospective, large-scale studies are warranted."

Journal • Preclinical • Endometriosis • Gynecology • Infertility • Women's Health

Comparison of the Live Birth Rate Between the PPOS and the GnRH Antagonist Protocol in Patients Undergoing IVF (clinicaltrials.gov) - P=N/A | N=220 | Terminated | Sponsor: ShangHai Ji Ai Genetics & IVF Institute | N=784 ➔ 220 | Trial completion date: Dec 2025 ➔ May 2025 | Recruiting ➔ Terminated | Trial primary completion date: Nov 2024 ➔ May 2025; The study was terminated due to difficulty in recruiting patients.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Gynecology • Infertility • Sexual Disorders

Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Patients Undergoing PGT-A (clinicaltrials.gov) - P3 | N=400 | Completed | Sponsor: ShangHai Ji Ai Genetics & IVF Institute | Recruiting ➔ Completed | Trial completion date: Dec 2025 ➔ May 2025

Trial completion • Trial completion date

Effects of kuntai capsule in combination with hormone replacement therapy on premature ovarian failure and bone metabolism. (PubMed, Afr J Reprod Health) - "A total of 190 POF patients were randomly assigned to either a control group (n=95) receiving HRT alone (1 mg estradiol valerate tablets and 10 mg dydrogesterone tablets), or an observation group (n=95) receiving a combination of HRT and Kuntai Capsule. The observation group also had a significantly lower recurrence rate (7.3%) after 24 months, compared to the control group (16.8%). These results suggest that the combination of Kuntai Capsule and HRT offers a promising treatment for POF, improving ovarian function, hormone levels, and bone health while reducing recurrence risk."

Clinical • Journal • Women's Health

Comprehensive Review of Hormone Therapy in Menopause: Cardiovascular and Metabolic Impacts in Women with Obesity (ECO 2025) - "A randomized control trial on CEE combined with natural progesterone or dydrogesterone demonstrated significant improvements in HDL-C and LDL-C levels, but increased triglyceride concentrations (p = 0.140), especially at higher doses. Hormone therapy in women with obesity in postmenopause demonstrated a wide range of metabolic and cardiovascular effects, with significant variations depending on the type, dose, and method of administration of hormonal agents. Low-dose transdermal estradiol offers a favorable safety profile for improving vascular function, with minimal inflammatory risks. On the other hand, the use of CEE, although beneficial for lipid profiles, requires caution due to the potential to exacerbate hypertriglyceridemia."

Clinical • Review • Cardiovascular • Dyslipidemia • Genetic Disorders • Hypertriglyceridemia • Obesity

Treatment of Endometriosis – Focus on Improving Quality of Life (WCE 2025) - "The use of progestogens with affinity for receptors other than progesterone can lead to the development of side effects. In the presence of risks of endometriosis-associated complications, switching to dydrogesterone is recommended, since the presence of only a continuous regimen in dienogest limits its capabilities in terms of overcoming several undesirable effects. Group 2 patients were more likely to have endocrine and neurological diseases, which could possibly have influenced the occurrence of side effects and the need for early discontinuation of dienogest therapy."

HEOR • CNS Disorders • Depression • Endometriosis • Gynecology • Migraine • Pain • Psychiatry • Women's Health

Observational Open-Label Multicenter Study to Evaluate the Effects of Hormonal Therapy of Endometriosis: Stage 3-4 (the ORCHIDEA Study Subanalysis) (WCE 2025) - "Conclusion Based on the results of the study, it can be concluded that dydrogesterone is highly effective in the treatment of stage III-IV endometriosis. Prolonged cyclic and continuous treatment regimens have similar effectiveness in reducing chronic pelvic pain, improving quality of life and sexual well-being."

Clinical • Endometriosis • Gynecology • Musculoskeletal Pain • Pain • Women's Health